Acute Decompensated Heart Failure Management

Initial Assessment and Stabilization

• The American College of Cardiology recommends administering supplemental oxygen immediately to relieve hypoxemia-related symptoms, targeting oxygen saturation >90% 1
• Assess for impending respiratory failure requiring non-invasive ventilation or intubation in patients with respiratory rate of 33/min 1
• Rapidly determine two critical parameters: adequacy of systemic perfusion and volume status, checking for cool extremities, altered mental status, decreased urine output, narrow pulse pressure, jugular venous distension, pulmonary rales, and peripheral edema 1, 2

Diagnostic Workup

• The American College of Cardiology recommends ECG and cardiac troponin testing to identify acute coronary syndrome as a precipitating factor 1
• Perform chest radiograph to assess pulmonary congestion 1
• Measure BNP or NT-proBNP if diagnosis is uncertain 1
• Obtain baseline electrolytes, renal function, and complete blood count 1

Pharmacological Management

• The American College of Cardiology recommends starting intravenous loop diuretics immediately in the emergency department without delay, as early intervention improves outcomes 1
• If already on oral loop diuretics, the IV dose should equal or exceed the chronic oral daily dose 3
• If diuretic-naive, administer furosemide 40 mg IV bolus or equivalent (torsemide 20 mg, bumetanide 1 mg) 3
• Monitor urine output hourly and titrate dose upward if inadequate diuresis 3
• Consider administering intravenous inotropic drugs, such as dobutamine 2-5 μg/kg/min or milrinone 50 μg/kg loading dose, then 0.375-0.75 μg/kg/min, to maintain systemic perfusion in patients with hypoperfusion 4

Monitoring and Escalation of Care

• Continuously monitor patients during the acute phase, measuring fluid intake/output hourly, vital signs every 15-30 minutes initially, and daily weights at the same time 1, 3, 5
• Assess serum electrolytes, BUN, creatinine daily during IV diuretic use 3
• Consider invasive hemodynamic monitoring (pulmonary artery catheter) if respiratory distress persists, clinical evidence of impaired perfusion is present, or there is an inadequate response to initial therapy 1, 2, 3

Medications to Avoid

• Never use diltiazem or verapamil, as they worsen heart failure and increase hospitalization risk 6, 5
• Avoid NSAIDs during ACE inhibitor initiation 1
• Do not combine potassium-sparing diuretics during acute RAAS inhibitor initiation 1

Common Pitfalls

• Do not delay diuretic therapy, as waiting for admission or further testing worsens outcomes 1
• Do not stop beta-blockers abruptly unless cardiogenic shock is present - gradual down-titration if needed 2
• Do not over-diurese before starting long-term GDMT, as excessive volume depletion increases hypotension and AKI risk with ACE inhibitors 3

Management of Metabolic Alkalosis in HFrEF with Hypercapnic Respiratory Failure

Hemodynamic Monitoring

• In patients with systolic heart failure and reduced ejection fraction who develop hypercapnic respiratory failure, invasive hemodynamic monitoring should be continued to guide the balance between volume status and respiratory mechanics. 7

Diuretic Strategy

Continuation of Loop Diuretics

• Intravenous loop diuretics must be maintained at doses equal to or greater than the patient’s chronic oral regimen, even in the presence of metabolic alkalosis, to ensure ongoing decongestion. 7

Sequential Nephron Blockade

• If diuresis remains insufficient after adding acetazolamide, a second diuretic (e.g., metolazone or intravenous chlorothiazide) should be introduced to achieve sequential nephron blockade. [7][8]

Avoidance of Diuretic Cessation

• Stopping loop diuretics to “correct” the alkalosis is contraindicated because it worsens volume overload and can precipitate respiratory decompensation. [7][9]

Electrolyte and Neurohormonal Management

Aldosterone Antagonist, ACE‑I/ARB, and β‑Blocker Continuation

• Aldosterone antagonists (spironolactone or eplerenone) should be added or optimized, and ACE inhibitors/ARBs and β‑blockers continued unless hemodynamic instability or cardiogenic shock is present, to blunt neurohormonal activation that perpetuates bicarbonate retention. 7

Impact of Metabolic Alkalosis on Diuretic Efficacy

• Metabolic alkalosis diminishes loop diuretic effectiveness by lowering the intraluminal chloride gradient and stimulating adaptive neurohormonal pathways. 8

Chloride and Potassium Depletion

• Hypochloremia and hypokalemia synergistically sustain metabolic alkalosis and contribute to diuretic resistance. 8

Monitoring Parameters

• Daily laboratory assessment of electrolytes, blood urea nitrogen, and creatinine is required during active therapy to detect adverse shifts. 7
• Continuous monitoring of body weight, hourly fluid balance, and vital signs should be performed throughout the acute phase to guide titration of diuretics and adjunctive agents. 7

Escalation of Fluid Removal

• When conventional diuretic strategies fail to achieve adequate decongestion, ultrafiltration or hemofiltration should be considered to provide mechanical fluid removal, restore diuretic responsiveness, and allow separate management of the acid‑base disturbance. [7][9]

Pathophysiological Insight (Cited)

• Loop diuretic–induced chloride loss, activation of the renin‑angiotensin system, increased distal sodium delivery, and hypokalemia collectively promote urinary acidification and bicarbonate retention, reinforcing metabolic alkalosis. 8
• The combination of hypochloremia and metabolic alkalosis creates a feedback loop that antagonizes loop diuretic action, leading to diuretic resistance. 8